Literature DB >> 25597247

Down-regulation of the A3 adenosine receptor in human mast cells upregulates mediators of angiogenesis and remodeling.

Noam Rudich1, Ornit Dekel1, Ronit Sagi-Eisenberg2.   

Abstract

Adenosine activated mast cells have been long implicated in allergic asthma and studies in rodent mast cells have assigned the A3 adenosine receptor (A3R) a primary role in mediating adenosine responses. Here we analyzed the functional impact of A3R activation on genes that are implicated in tissue remodeling in severe asthma in the human mast cell line HMC-1 that shares similarities with lung derived human mast cells. Quantitative real time PCR demonstrated upregulation of IL6, IL8, VEGF, amphiregulin and osteopontin. Moreover, further upregulation of these genes was noted upon the addition of dexamethasone. Unexpectedly, activated A3R down regulated its own expression and knockdown of the receptor replicated the pattern of agonist induced gene upregulation. This study therefore identifies the human mast cell A3R as regulator of tissue remodeling gene expression in human mast cells and demonstrates a heretofore-unrecognized mode of feedback regulation that is exerted by this receptor.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  A3 adenosine receptor; Adenosine; HMC-1 cells; Mast cells; Tissue remodeling

Mesh:

Substances:

Year:  2015        PMID: 25597247     DOI: 10.1016/j.molimm.2014.12.015

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

Review 1.  The Role of Adenosine Receptor Activation in Attenuating Cartilaginous Inflammation.

Authors:  Jonathan M Bekisz; Christopher D Lopez; Carmen Corciulo; Aranzazu Mediero; Paulo G Coelho; Lukasz Witek; Roberto L Flores; Bruce N Cronstein
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 2.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

Review 3.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

Review 4.  Pathological overproduction: the bad side of adenosine.

Authors:  Pier Andrea Borea; Stefania Gessi; Stefania Merighi; Fabrizio Vincenzi; Katia Varani
Journal:  Br J Pharmacol       Date:  2017-03-31       Impact factor: 8.739

5.  Physiology and Transcriptomics Analysis Reveal the Contribution of Lungs on High-Altitude Hypoxia Adaptation in Tibetan Sheep.

Authors:  Pengfei Zhao; Fangfang Zhao; Jiang Hu; Jiqing Wang; Xiu Liu; Zhidong Zhao; Qiming Xi; Hongxian Sun; Shaobin Li; Yuzhu Luo
Journal:  Front Physiol       Date:  2022-05-12       Impact factor: 4.755

Review 6.  Purinergic signaling in scarring.

Authors:  Davide Ferrari; Roberto Gambari; Marco Idzko; Tobias Müller; Cristina Albanesi; Saveria Pastore; Gaetano La Manna; Simon C Robson; Bruce Cronstein
Journal:  FASEB J       Date:  2015-09-02       Impact factor: 5.191

7.  Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals.

Authors:  Zhenyu Ou; Yao He; Lin Qi; Xiongbin Zu; Longxiang Wu; Zhenzhen Cao; Yuan Li; Longfei Liu; Daud Athanasius Dube; Zhi Wang; Long Wang
Journal:  Oncotarget       Date:  2017-07-22

Review 8.  Adenosine Signaling in Mast Cells and Allergic Diseases.

Authors:  Lucia Garcia-Garcia; Laia Olle; Margarita Martin; Jordi Roca-Ferrer; Rosa Muñoz-Cano
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

9.  Mast Cells Are Directly Activated by Cancer Cell-Derived Extracellular Vesicles by a CD73- and Adenosine-Dependent Mechanism.

Authors:  Yaara Gorzalczany; Ofer Merimsky; Ronit Sagi-Eisenberg
Journal:  Transl Oncol       Date:  2019-09-04       Impact factor: 4.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.